Bollard Group’s Takeda Pharmaceutical TAK Stock Holding History

Bollard Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-152	Closed	-$2K	–	365
2023 Q3	$2K	Hold	152	–	–	﹤0.01%	332
2023 Q2	$2K	Buy	+152	New	+$2.49K	﹤0.01%	554

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bollard Group's TAK Position: Q4 2023 in Review

Bollard Group sold out of Takeda Pharmaceutical (TAK) in Q4 2023, closing a stake of 152 shares — an estimated $2K sold.

Bollard Group first reported a position in TAK in Q2 2023 and held it in 2 quarters. The position peaked at $2K in Q3 2023. 306 funds tracked by Wall St. Rank hold TAK as of Q4 2023.

Bollard Group reported no remaining Takeda Pharmaceutical position as of Q4 2023 after selling out during the quarter.
Bollard Group sold 152 Takeda Pharmaceutical shares in Q4 2023, an estimated $2K.
Bollard Group first reported a position in Takeda Pharmaceutical in Q2 2023 and held it in 2 quarters.
Bollard Group's Takeda Pharmaceutical position peaked at $2K in Q3 2023.
306 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2023.

Based on Bollard Group's 13F filing for Q4 2023, filed 13 Feb 2024.